The Europe Infertility Drugs Market should witness market growth of 6.0% CAGR during the forecast period (2022-2028).
A chorionic gonadotropin injection typically costs USD 397.83 per vial without health insurance and USD 304.76 per vial with insurance. In addition, Bharat Serums and Vaccines Limited started a phase 3 clinical research in March 2022 to examine the safety and effectiveness of recombinant human follicle-stimulating hormone (900 IU) in female patients between the ages of 20 and 39. Moreover, a phase 3 clinical study for the ovarian stimulation drug QL1012, which is now being manufactured by Qilu Pharmaceutical Co., Ltd.
Therefore, the anticipated release of gonadotropins may promote the maintenance of dominance at the maximum growth rate during the foreseeable timeframe. The ovulation-stimulating medications for female infertility are used to treat infertile women and those with ovulation disorders. Some of the most popular medications for female infertility are clomiphene citrate, letrozole, gonadotropins, metformin, and bromocriptine.
With over 7 million predicted deaths from tobacco use in 2016, many of them happening early, and huge losses of healthy life owing to illness and disability, tobacco use has a major negative impact on health. With an estimated 209 million smokers (or 29% of the population), the European Region has the highest rate of tobacco usage in the whole globe. It is anticipated that half of the smokers will die prematurely as a consequence of their tobacco use, and tobacco use increases the risk and burden of illness overall in communities. Therefore, all of these reasons are driving the market for infertility medications in Europe.
The Germany market dominated the Europe Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $321.6 million by 2028. The UK market is exhibiting a CAGR of 5.1% during (2022-2028). Additionally, The France market would experience a CAGR of 6.8% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
A chorionic gonadotropin injection typically costs USD 397.83 per vial without health insurance and USD 304.76 per vial with insurance. In addition, Bharat Serums and Vaccines Limited started a phase 3 clinical research in March 2022 to examine the safety and effectiveness of recombinant human follicle-stimulating hormone (900 IU) in female patients between the ages of 20 and 39. Moreover, a phase 3 clinical study for the ovarian stimulation drug QL1012, which is now being manufactured by Qilu Pharmaceutical Co., Ltd.
Therefore, the anticipated release of gonadotropins may promote the maintenance of dominance at the maximum growth rate during the foreseeable timeframe. The ovulation-stimulating medications for female infertility are used to treat infertile women and those with ovulation disorders. Some of the most popular medications for female infertility are clomiphene citrate, letrozole, gonadotropins, metformin, and bromocriptine.
With over 7 million predicted deaths from tobacco use in 2016, many of them happening early, and huge losses of healthy life owing to illness and disability, tobacco use has a major negative impact on health. With an estimated 209 million smokers (or 29% of the population), the European Region has the highest rate of tobacco usage in the whole globe. It is anticipated that half of the smokers will die prematurely as a consequence of their tobacco use, and tobacco use increases the risk and burden of illness overall in communities. Therefore, all of these reasons are driving the market for infertility medications in Europe.
The Germany market dominated the Europe Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $321.6 million by 2028. The UK market is exhibiting a CAGR of 5.1% during (2022-2028). Additionally, The France market would experience a CAGR of 6.8% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
By End-user
- Women
- Men
By Distribution Channel
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Online Pharmacy
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Infertility Drugs Market, by End User
1.4.2 Europe Infertility Drugs Market, by Distribution Channel
1.4.3 Europe Infertility Drugs Market, by Drug Class
1.4.4 Europe Infertility Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Infertility Drugs Market by End-user
3.1 Europe Women Market by Country
3.2 Europe Men Market by Country
Chapter 4. Europe Infertility Drugs Market by Distribution Channel
4.1 Europe Hospital Pharmacy Market by Country
4.2 Europe Specialty & Retail Pharmacy Market by Country
4.3 Europe Online Pharmacy Market by Country
Chapter 5. Europe Infertility Drugs Market by Drug Class
5.1 Europe Gonadotropins Market by Country
5.2 Europe Aromatase Inhibitors Market by Country
5.3 Europe Selective Estrogen Receptor Modulators (SERMs) Market by Country
5.4 Europe Dopamine Agonists Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe Infertility Drugs Market by Country
6.1 Germany Infertility Drugs Market
6.1.1 Germany Infertility Drugs Market by End-user
6.1.2 Germany Infertility Drugs Market by Distribution Channel
6.1.3 Germany Infertility Drugs Market by Drug Class
6.2 UK Infertility Drugs Market
6.2.1 UK Infertility Drugs Market by End-user
6.2.2 UK Infertility Drugs Market by Distribution Channel
6.2.3 UK Infertility Drugs Market by Drug Class
6.3 France Infertility Drugs Market
6.3.1 France Infertility Drugs Market by End-user
6.3.2 France Infertility Drugs Market by Distribution Channel
6.3.3 France Infertility Drugs Market by Drug Class
6.4 Russia Infertility Drugs Market
6.4.1 Russia Infertility Drugs Market by End-user
6.4.2 Russia Infertility Drugs Market by Distribution Channel
6.4.3 Russia Infertility Drugs Market by Drug Class
6.5 Spain Infertility Drugs Market
6.5.1 Spain Infertility Drugs Market by End-user
6.5.2 Spain Infertility Drugs Market by Distribution Channel
6.5.3 Spain Infertility Drugs Market by Drug Class
6.6 Italy Infertility Drugs Market
6.6.1 Italy Infertility Drugs Market by End-user
6.6.2 Italy Infertility Drugs Market by Distribution Channel
6.6.3 Italy Infertility Drugs Market by Drug Class
6.7 Rest of Europe Infertility Drugs Market
6.7.1 Rest of Europe Infertility Drugs Market by End-user
6.7.2 Rest of Europe Infertility Drugs Market by Distribution Channel
6.7.3 Rest of Europe Infertility Drugs Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Bayer AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Acquisition and Mergers:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Merck & Co., Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Ferring Holdings SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research and Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Organon & Co.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Mankind Pharma Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Product Launches and Product Expansions:
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Methodology
LOADING...
